Concepedia

Author

C. Serradeil‐Le Gal

Sanofi (France)ORCID

Also Known As

C Serradeil-Le Gal, C Serradeil‐Le Gal, C. Gal, C. Serradeil-Le Gal, C. Serradeil‐Le Gal, C.Serradeil-Le Gal, Charline Gal, Csenge Gál

29

Publications

1.1K

Citations

14

H-Index

32

Concepts

All Affiliations

Sanofi (France)InsermHôpitaux Universitaires Henri-Mondor
CS

About

C. Serradeil‐Le Gal is an author at Sanofi (France) specializing in physiology, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

9

9

876

2

Biochemistry

4

4

415

3

Cell Biology

3

3

161

4

Natural Sciences

2

2

122

5

Health Sciences

1

1

103

C. Serradeil‐Le Gal

×

12

Publications

956

Citations

12

H-Index

YearCitations

Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

C. Serradeil‐Le Gal, Jean Wagnon, Corinne Garcia,

Journal of Clinical Investigation

1993

272

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

C. Serradeil‐Le Gal, C Lacour, G Valette,

Journal of Clinical Investigation

1996

247

Endothelin action in rat liver. Receptors, free Ca2+ oscillations, and activation of glycogenolysis.

C. Serradeil‐Le Gal, Catherine Jouneaux, A Sanchez-Bueno,

Journal of Clinical Investigation

1991

110

Growth inhibitory properties of endothelin-1 in activated human hepatic stellate cells: a cyclic adenosine monophosphate-mediated pathway. Inhibition of both extracellular signal-regulated kinase and c-Jun kinase and upregulation of endothelin B receptors.

Ariane Mallat, Anne-Marie Préaux, C. Serradeil‐Le Gal,

Journal of Clinical Investigation

1996

103

Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells

C. Serradeil‐Le Gal, Jean‐Marc Herbert, Chantal Delisée,

American Journal of Physiology-Heart and Circulatory Physiology

1995

53

V2 Receptor Antagonism of DDAVP-Induced Release of Hemostasis Factors in Conscious Dogs

A. Bernat, Pascal Hoffmann, A. Dumas,

Journal of Pharmacology and Experimental Therapeutics

1997

44

Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on swiss 3T3 cells

C. Serradeil‐Le Gal, B. Bourrié, Danielle Raufaste,

Biochemical Pharmacology

1994

30

Importance of the phenotypic state of vascular smooth muscle cells on the binding and the mitogenic activity of endothelin

C. Serradeil‐Le Gal, Jean‐Marc Herbert, Corine Garcia,

Peptides

1991

28

Key Amino Acids Located within the Transmembrane Domains 5 and 7 Account for the Pharmacological Specificity of the Human V1b Vasopressin Receptor

Sylvain Derick, Ana Peña, Thierry Durroux,

Molecular Endocrinology

2004

21

Effects of SR 49059, a non‐peptide antagonist of vasopressin V<sub>1a</sub>receptors, on vasopressin‐induced coronary vasoconstriction in conscious rabbits

C. Serradeil‐Le Gal, G. Villanova, Michel Boutin,

Fundamental and Clinical Pharmacology

1995

19

Page 1